Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
BREAST CARE(2024)
Key words
Oncotype DX Breast Recurrence Score (R) test,Chemotherapy,Budget impact model (costs, cost-effectiveness),Gene expression test,Breast cancer
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined